<DOC>
	<DOCNO>NCT00408187</DOCNO>
	<brief_summary>The purpose study determine safety efficacy voclosporin patient plaque psoriasis .</brief_summary>
	<brief_title>Randomized , Placebo Ciclosporin Controlled Study ISA247 Plaque Psoriasis Patients</brief_title>
	<detailed_description>Psoriasis chronic skin condition significant impact patient 's physical mental well . The common form psoriasis plaque psoriasis . Targeted treatment psoriasis report recently , yet ciclosporin , calcineurin inhibitor ( CNi ) remain one treatment great efficacy . Voclosporin represent possibility calcineurin inhibitor efficacious ciclosporin A , also improve toxicity profile .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Aged great equal 18 year age inclusive time screen . Diagnosed plaque psoriasis great equal 6 month prior screen . Diagnosis stable , plaque psoriasis ; i.e . psoriasis must spontaneously improve worsen 4 week prior screen visit . Psoriasis fail least one systemic treatment regimen systemic therapy contraindicate tolerability issue . Plaque psoriasis involve great equal 10 % body surface area SPGA score great equal 3 screen prior randomization day 0 visit . Not pregnant nursing . Sexually active woman childbearing potential less 1 year postmenopausal sexually active men surgically sterile must use reliable form birth control study treatment least 3 month last dose study drug . Surgically sterile female consider childbearing potential . Reliable form birth control include oral depot contraceptive , doublebarrier method . Written inform consent prior washout screen procedure . Able keep study appointment cooperate study requirement , opinion Investigator . Has generalize erythrodermic , guttate , pustular psoriasis . Have dermatosis would interfere evaluation psoriasis , discretion Investigator . A current malignancy history malignancy within 5 year history lymphoma time . Subjects enrol history squamous basal cell carcinoma surgically excise remove curettage electrodesiccation . Has current , uncontrolled bacterial , viral , fungal infection require intravenous antibiotic antifungal infection within 60 day prior screen . A known history tuberculosis . Serologic evidence know latent HIV , HBV HCV virus . Uncontrolled hypertension systolic blood pressure great equal 160 mmHg diastolic blood pressure great equal 90 mmHg . MDRD GFR &lt; 60 mL/min . Variation screen Visit 1 SCr great equal 30 % . ALT , AST , GGT great equal 2x upper limit normal ( ULN ) . White blood cell count less equal 2.8 x 10 ninth power/L . Requires follow prohibited medication treatment washout treatment period : drug potentiate nephrotoxicity voclosporin , drug interfere pharmacokinetics , drug consider contribute psoriasis flare ; , systemic topical psoriasis medication may interfere assessment study drug efficacy . Has use investigational drug device within 30 day 10 half life ( whichever longer ) prior screen visit . Current participation another clinical trial drug biological agent . Has take biological agent ( ) , except flu shot , tetanus shot , booster , within 3 month randomization . Biological agent include virus , live vaccine , therapeutic serum , toxin , antitoxin , monoclonal antibody analogous product applicable prevention , treatment , cure disease injuries man . Previous exposure voclosporin . A history clinically define allergy ciclosporin , constituent Neoral constituent ISA247 formulation . A history alcoholism drug addiction . Weighs &lt; 45kg ( 99 lb ) . A history disease , include mental/emotional disorder would interfere subject 's participation study , evaluation his/her response might cause administration voclosporin pose significant risk subject , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Adult</keyword>
	<keyword>Chronic Disease</keyword>
	<keyword>Dermatologic Agents</keyword>
	<keyword>Female</keyword>
	<keyword>Humans</keyword>
	<keyword>Male</keyword>
	<keyword>Middle Aged</keyword>
	<keyword>Severity Illness Index</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Double-Blind Method</keyword>
</DOC>